Most Read Articles
Jairia Dela Cruz, 22 Apr 2020
A wristwatch-like device that monitors pulse, breathing and blood oxygen levels of the user allows physicians to provide care remotely both in hospital and nontraditional settings, and may help in the fight against the coronavirus disease 2019 (COVID-19) pandemic.
Roshini Claire Anthony, 6 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Pank Jit Sin, 21 May 2020

Persons suffering from asthma should pay particular attention to SARS-CoV-2 precautionary measures such as social distancing, regular handwashing, and wearing of masks on top of keeping their asthma in control. This is because data collected so far paints a bleaker picture for asthmatics than the normal population should they catch COVID-19.

Stephen Padilla, 6 days ago
Herd immunity will not work in the novel coronavirus disease (COVID-19), according to an infectious disease expert who addressed over 3,600 primary care physicians (PCP) from Asia Pacific at the inaugural webcast of the MIMS COVID Conversations Series.

HCC risk remains elevated in cirrhotic patients even after HCV clearance

22 Nov 2019
Authorities in Malaysia have approved a compulsory license for Hepatitis C treatment, which allows for cheaper generic medication to be produced without the drug patent holder’s consent.

Cirrhotic patients continue to suffer from excess hepatocellular carcinoma (HCC) risk for years even after clearance of hepatitis C virus (HCV) infection, a recent study has found.

The study included 48,135 HCV patients who initiated antiviral treatment and attained sustained virologic response (SVR). Patients were followed for a mean of 5.4 years for the surveillance of HCC development.

Of 9,784 patients with pretreatment cirrhosis, 850 developed HCC over a mean follow-up of 3.9 years. In those treated with direct-acting antivirals, the malignancy was significantly more likely to occur in those with fibrosis-4 scores ≥3.25 (adjusted hazard ratio [HR], 2.14, 95 percent confidence intervals [CI], 1.66–2.75). The same was true for those treated with interferon (adjusted HR, 2.78, 95 percent CI, 1.91–4.03).

HCC risk declined by 3.8 percent per year in the first year after SVR in patients with pretreatment cirrhosis, fibrosis-4 scores ≥3.25 and treated with DAAs. By the fourth year, annual decline was at 2.4 percent per year (p=0.01).

However, in such patients who were instead treated with interferons, the annual HCC risk remained above 2 percent even 10 years after SVR. This risk estimate was obtained despite the more than 50-percent drop in HCC risk associated with a transition in fibrosis scores from ≥3.25 before to <3.25 after SVR.

Patients without cirrhosis before treatment had a consistently low risk of HCC, except for those with fibrosis-4 scores ≥3.25 either before (1.22 percent per year) or after (2.39 percent per year) SVR.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 22 Apr 2020
A wristwatch-like device that monitors pulse, breathing and blood oxygen levels of the user allows physicians to provide care remotely both in hospital and nontraditional settings, and may help in the fight against the coronavirus disease 2019 (COVID-19) pandemic.
Roshini Claire Anthony, 6 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Pank Jit Sin, 21 May 2020

Persons suffering from asthma should pay particular attention to SARS-CoV-2 precautionary measures such as social distancing, regular handwashing, and wearing of masks on top of keeping their asthma in control. This is because data collected so far paints a bleaker picture for asthmatics than the normal population should they catch COVID-19.

Stephen Padilla, 6 days ago
Herd immunity will not work in the novel coronavirus disease (COVID-19), according to an infectious disease expert who addressed over 3,600 primary care physicians (PCP) from Asia Pacific at the inaugural webcast of the MIMS COVID Conversations Series.